

Patient card for safe use

Translation of the
PEI-approved Patient Card
(Version 13.0, German)

Please also read the package leaflet (package insert)
for Opdivo carefully.

OPDIVO (nivolumab)

This training material was mandated as a risk minimization measure
and coordinated with the Paul Ehrlich Institute (PEI).

Version 13.0, version of the information February 2026

IMPORTANT information for patients

Carry this card with you at all times to inform healthcare
professionals that you are receiving treatment with

- nivolumab or
- nivolumab in combination with YERVOY® (ipilimumab)



Nivolumab can increase the risk of serious or even
life-threatening side effects, which may affect
different parts of the body. If you have any signs and
symptoms, tell your doctor right away. This includes
any possible side effects not included in this card or
in the nivolumab package leaflet.

POSSIBLE SIDE EFFECTS



Chest
(heart and
lungs)

Breathing difficulties, cough, wheeze,
chest pain, irregular heartbeat,
palpitations (increased awareness
of your heartbeat)



Gut
(stomach
and bowels)

Diarrhoea (watery, loose or soft stools),
blood or mucus in stools, dark-coloured
stools, pain or tenderness in your
stomach or abdominal area



Liver

Eye or skin yellowing (jaundice),
pain on the right side of your
stomach area



Kidneys

Change in amount and/or
frequency of urine



Hormone-
producing
glands
(including
diabetes)

Headaches, blurry or double vision,
fatigue (tiredness), weight changes,
behavioural changes (eg, lower sex
drive, irritability or forgetfulness),
excessive thirst, increased appetite
with weight loss, weakness,
drowsiness, depression, feeling unwell,
change in amount and/or frequency
of urine



Skin

Rash, itching, blisters and/or peeling
of the skin (possibly fatal), ulcers,
dry skin, skin nodules



Other

Weakness, fatigue (tiredness),
decreased appetite, nausea, vomiting,
tingling or numbness in arms and legs,
difficulty walking, fever, swollen lymph
nodes, headache, seizures, stiff neck,
confusion, drowsiness, muscle pain,
stiffness, dark urine, eye pain or redness,
blurry vision, or other vision problems

IMPORTANT

- Tell your doctor of any previous medical conditions, including if you have had a stem cell transplant that uses donor stem cells (allogeneic).
 - Early assessment and management of side effects by your doctor reduces the likelihood that treatment with nivolumab or nivolumab in combination with ipilimumab will need to be temporarily or permanently stopped.
-
- Signs and symptoms that may appear mild can quickly worsen if left untreated.
 - **DO NOT** try to treat these symptoms yourself.
 - Signs and symptoms can appear during treatment or may be delayed and may occur weeks to months after your last infusion/injection.



For further information, please refer to the package leaflet of Opdivo (see website <https://www.bms.com/de/our-medicines.html#opdivo> and the QR code shown here) or contact the company: Email: medwiss.info@bms.com, phone: 0800 0752002.

IMPORTANT information for healthcare professionals

- This patient is being treated with **nivolumab** or **nivolumab in combination with ipilimumab**.
- Immune-related adverse reactions may appear at any time during treatment or months after its discontinuation.
- Early diagnosis and appropriate management are essential to minimize life-threatening complications.
- Immediate contact with an experienced practitioner may be helpful for management of organ-specific immune-related adverse reactions.



Please consult the summary of product characteristics of Opdivo (see website <https://www.bms.com/de/our-medicines.html#opdivo> and the QR code shown here) or contact the company: Email: medwiss.info@bms.com, phone: 0800 0752002.

The healthcare professional treating this patient with nivolumab or nivolumab in combination with YERVOY should complete the "My Doctor's Contact Information" of this Patient Card.

My Doctor's Contact Information

(who prescribed nivolumab or nivolumab in combination with ipilimumab)

Name of Doctor:

Office Phone:

After-Hours Phone:

My Contact Information

My name:

My phone number:

Emergency Contact (name and phone number):

Reporting of side effects

Reporting side effects is of great importance for continuous monitoring of the benefit-risk ratio of medicinal products. Please report side effects to:

Paul-Ehrlich-Institut
Paul-Ehrlich-Straße 51–59
63225 Langen, www.pei.de
Email: pharmakovigilanz@pei.de

or to:

Bristol-Myers Squibb GmbH & Co. KGaA
80632 Munich, Email: medwiss.info@bms.com
Phone: 0800 0752002